Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies.

Pinal-Fernandez I, Mecoli CA, Casal-Dominguez M, Pak K, Hosono Y, Huapaya J, Huang W, Albayda J, Tiniakou E, Paik JJ, Johnson C, Danoff SK, Corse AM, Christopher-Stine L, Mammen AL.

Neurology. 2019 Oct 8. pii: 10.1212/WNL.0000000000008443. doi: 10.1212/WNL.0000000000008443. [Epub ahead of print]

PMID:
31594859
2.

Identification of distinctive interferon gene signatures in different types of myositis.

Pinal-Fernandez I, Casal-Dominguez M, Derfoul A, Pak K, Plotz P, Miller FW, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Paik J, Albayda J, Christopher-Stine L, Lloyd TE, Corse AM, Mammen AL.

Neurology. 2019 Sep 17;93(12):e1193-e1204. doi: 10.1212/WNL.0000000000008128. Epub 2019 Aug 21.

PMID:
31434690
3.

Myositis Autoantibodies: A Comparison of Results from the Oklahoma Medical Research Foundation Myositis Panel to the Euroimmun Research Line Blot.

Mecoli CA, Casal-Dominguez M, Pak K, Pinal-Fernandez I, Albayda J, Tiniakou E, Paik JJ, Zahid U, Danoff SK, Mammen AL, Casciola-Rosen L, Christopher-Stine L.

Arthritis Rheumatol. 2019 Aug 20. doi: 10.1002/art.41088. [Epub ahead of print]

PMID:
31430029
4.

Reader response: Pearls & Oy-sters: Pembrolizumab-induced myasthenia gravis.

Robbins NM, Mozaffar T, Mammen AL, Liewluck T, Guidon A, Lawson VH.

Neurology. 2019 Jul 23;93(4):183-184. doi: 10.1212/WNL.0000000000007845. No abstract available.

PMID:
31332091
5.

Long-Term Treatment With Azathioprine and Mycophenolate Mofetil for Myositis-Related Interstitial Lung Disease.

Huapaya JA, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ, Sanyal A, Mammen AL, Christopher-Stine L, Danoff SK.

Chest. 2019 Jun 22. pii: S0012-3692(19)31200-0. doi: 10.1016/j.chest.2019.05.023. [Epub ahead of print]

PMID:
31238042
6.

On using machine learning algorithms to define clinically meaningful patient subgroups.

Pinal-Fernandez I, Mammen AL.

Ann Rheum Dis. 2019 Jun 21. pii: annrheumdis-2019-215852. doi: 10.1136/annrheumdis-2019-215852. [Epub ahead of print] No abstract available.

PMID:
31227486
7.

Response to: 'response to: 'Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis' by Sabbagh S et al' by Yang et al.

Sabbagh S, Pinal Fernandez I, Miller FW, Rider LG, Mammen AL.

Ann Rheum Dis. 2019 Jun 17. pii: annrheumdis-2019-215693. doi: 10.1136/annrheumdis-2019-215693. [Epub ahead of print] No abstract available.

PMID:
31208959
8.

Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease.

Huapaya JA, Hallowell R, Silhan L, Pinal-Fernandez I, Casal-Dominguez M, Johnson C, Albayda J, Paik JJ, Lin CT, Hussien A, Mammen AL, Christopher-Stine L, Danoff SK.

Respir Med. 2019 Jul - Aug;154:6-11. doi: 10.1016/j.rmed.2019.05.012. Epub 2019 May 21.

PMID:
31176796
9.

Treatment of Refractory Anti-HMG-CoA Reductase Myopathy: A Role for Rituximab?

Mammen AL.

J Rheumatol. 2019 Jun;46(6):550-551. doi: 10.3899/jrheum.181392. No abstract available.

PMID:
31154443
10.

Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups.

Rothwell S, Chinoy H, Lamb JA, Miller FW, Rider LG, Wedderburn LR, McHugh NJ, Mammen AL, Betteridge ZE, Tansley SL, Bowes J, Vencovský J, Deakin CT, Dankó K, Vidya L, Selva-O'Callaghan A, Pachman LM, Reed AM, Molberg Ø, Benveniste O, Mathiesen PR, Radstake TRDJ, Doria A, de Bleecker J, Lee AT, Hanna MG, Machado PM, Ollier WE, Gregersen PK, Padyukov L, O'Hanlon TP, Cooper RG, Lundberg IE; Myositis Genetics Consortium (MYOGEN).

Ann Rheum Dis. 2019 Jul;78(7):996-1002. doi: 10.1136/annrheumdis-2019-215046. Epub 2019 May 28.

11.

Efficacy and adverse effects of methotrexate compared with azathioprine in the antisynthetase syndrome.

Casal-Dominguez M, Pinal-Fernandez I, Huapaya J, Albayda J, Paik JJ, Johnson C, Silhan L, Mammen AL, Danoff SK, Christopher-Stine L.

Clin Exp Rheumatol. 2019 Sep-Oct;37(5):858-861. Epub 2019 Apr 29.

12.

Use of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Statin-Associated Immune-Mediated Necrotizing Myopathy: A Case Series.

Tiniakou E, Rivera E, Mammen AL, Christopher-Stine L.

Arthritis Rheumatol. 2019 Oct;71(10):1723-1726. doi: 10.1002/art.40919. Epub 2019 Aug 6.

PMID:
31058470
13.

Amyloid-PET: a new tool for diagnosing IBM?

Pinal-Fernandez I, Mammen AL.

Nat Rev Rheumatol. 2019 Jun;15(6):321-322. doi: 10.1038/s41584-019-0223-9. No abstract available.

PMID:
31048779
14.

Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis.

Sabbagh S, Pinal-Fernandez I, Kishi T, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.

Ann Rheum Dis. 2019 Jul;78(7):988-995. doi: 10.1136/annrheumdis-2018-215004. Epub 2019 Apr 24.

PMID:
31018961
15.

The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease.

Brusca RM, Pinal-Fernandez I, Psoter K, Paik JJ, Albayda J, Mecoli C, Tiniakou E, Mammen AL, Christopher-Stine L, Danoff S, Johnson C.

Respir Med. 2019 Apr;150:63-65. doi: 10.1016/j.rmed.2019.02.015. Epub 2019 Feb 21.

PMID:
30961952
16.

Myositis Autoantigen Expression Correlates With Muscle Regeneration but Not Autoantibody Specificity.

Pinal-Fernandez I, Amici DR, Parks CA, Derfoul A, Casal-Dominguez M, Pak K, Yeker R, Plotz P, Milisenda JC, Grau-Junyent JM, Selva-O'Callaghan A, Paik JJ, Albayda J, Corse AM, Lloyd TE, Christopher-Stine L, Mammen AL.

Arthritis Rheumatol. 2019 Aug;71(8):1371-1376. doi: 10.1002/art.40883. Epub 2019 Jun 18.

PMID:
30861336
17.

Muscular and extramuscular features of myositis patients with anti-U1-RNP autoantibodies.

Casal-Dominguez M, Pinal-Fernandez I, Corse AM, Paik J, Albayda J, Casciola-Rosen L, Johnson C, Danoff SK, Christopher-Stine L, Tiniakou E, Mammen AL.

Neurology. 2019 Mar 26;92(13):e1416-e1426. doi: 10.1212/WNL.0000000000007188. Epub 2019 Mar 1.

PMID:
30824556
18.

Successful treatment of refractory mechanic's hands with ustekinumab in a patient with the antisynthetase syndrome.

Pinal-Fernandez I, Kroodsma CT, Mammen AL.

Rheumatology (Oxford). 2019 Jul 1;58(7):1307-1308. doi: 10.1093/rheumatology/kez020. No abstract available.

PMID:
30793759
19.

Corrigendum: Persistent upregulation of the β-tubulin tubb6, linked to muscle regeneration, is a source of microtubule disorganization in dystrophic muscle.

Randazzo D, Khalique U, Belanto JJ, Kenea A, Talsness DM, Olthoff JT, Tran MD, Zaal KJ, Pak K, Pinal-Fernandez I, Mammen AL, Sackett D, Ervasti JM, Ralston E.

Hum Mol Genet. 2019 Jun 1;28(11):1930. doi: 10.1093/hmg/ddz035. No abstract available.

20.

Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy.

Mohassel P, Landon-Cardinal O, Foley AR, Donkervoort S, Pak KS, Wahl C, Shebert RT, Harper A, Fequiere P, Meriggioli M, Toro C, Drachman D, Allenbach Y, Benveniste O, Béhin A, Eymard B, Lafôret P, Stojkovic T, Mammen AL, Bönnemann CG.

Neurol Neuroimmunol Neuroinflamm. 2018 Dec 12;6(1):e523. doi: 10.1212/NXI.0000000000000523. eCollection 2019 Jan.

21.

Persistent upregulation of the β-tubulin tubb6, linked to muscle regeneration, is a source of microtubule disorganization in dystrophic muscle.

Randazzo D, Khalique U, Belanto JJ, Kenea A, Talsness DM, Olthoff JT, Tran MD, Zaal KJ, Pak K, Pinal-Fernandez I, Mammen AL, Sackett D, Ervasti JM, Ralston E.

Hum Mol Genet. 2019 Apr 1;28(7):1117-1135. doi: 10.1093/hmg/ddy418. Erratum in: Hum Mol Genet. 2019 Jun 1;28(11):1930.

22.

Myopathy: Recent Progress, Current Therapies, and Future Directions.

Mammen AL, Roda RH, Leung DG.

Neurotherapeutics. 2018 Oct;15(4):837-839. doi: 10.1007/s13311-018-00688-y. No abstract available.

23.

Immune Checkpoint Inhibitor-Associated Myositis.

Anquetil C, Salem JE, Lebrun-Vignes B, Johnson DB, Mammen AL, Stenzel W, Léonard-Louis S, Benveniste O, Moslehi JJ, Allenbach Y.

Circulation. 2018 Aug 14;138(7):743-745. doi: 10.1161/CIRCULATIONAHA.118.035898. No abstract available.

PMID:
30359135
24.

Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1.

Mammen AL, Rajan A, Pak K, Lehky T, Casciola-Rosen L, Donahue RN, Lepone LM, Zekeridou A, Pittock SJ, Hassan R, Schlom J, Gulley JL.

Ann Rheum Dis. 2019 Jan;78(1):150-152. doi: 10.1136/annrheumdis-2018-213777. Epub 2018 Sep 5. No abstract available.

PMID:
30185415
25.

Dermatomyositis etiopathogenesis: a rebel soldier in the muscle.

Pinal-Fernandez I, Mammen AL.

Curr Opin Rheumatol. 2018 Nov;30(6):623-629. doi: 10.1097/BOR.0000000000000540. Review.

PMID:
30148802
26.

Classification and management of adult inflammatory myopathies.

Selva-O'Callaghan A, Pinal-Fernandez I, Trallero-Araguás E, Milisenda JC, Grau-Junyent JM, Mammen AL.

Lancet Neurol. 2018 Sep;17(9):816-828. doi: 10.1016/S1474-4422(18)30254-0. Review.

PMID:
30129477
27.

Muscle endurance deficits in myositis patients despite normal manual muscle testing scores.

Amici DR, Pinal-Fernandez I, Pagkatipunan R, Mears A, de Lorenzo R, Tiniakou E, Albayda J, Paik JJ, Lloyd TE, Christopher-Stine L, Mammen AL, Chung T.

Muscle Nerve. 2019 Jan;59(1):70-75. doi: 10.1002/mus.26307. Epub 2018 Dec 18.

PMID:
30028529
28.

Muscular and extramuscular clinical features of patients with anti-PM/Scl autoantibodies.

De Lorenzo R, Pinal-Fernandez I, Huang W, Albayda J, Tiniakou E, Johnson C, Milisenda JC, Casal-Dominguez M, Corse AM, Danoff SK, Christopher-Stine L, Paik JJ, Mammen AL.

Neurology. 2018 Jun 5;90(23):e2068-e2076. doi: 10.1212/WNL.0000000000005638. Epub 2018 May 4.

29.

The effect of cigarette smoking on the clinical and serological phenotypes of polymyositis and dermatomyositis.

Schiffenbauer A, Faghihi-Kashani S, O'Hanlon TP, Flegel WA, Adams SD, Targoff IN, Oddis CV, Ytterberg SR, Aggarwal R, Christopher-Stine L, Shamim EA, Dellaripa PF, Danoff SK, Mammen AL, Miller FW.

Semin Arthritis Rheum. 2018 Dec;48(3):504-512. doi: 10.1016/j.semarthrit.2018.02.003. Epub 2018 Feb 14.

PMID:
29703532
30.

Immune-Mediated Necrotizing Myopathy.

Pinal-Fernandez I, Casal-Dominguez M, Mammen AL.

Curr Rheumatol Rep. 2018 Mar 26;20(4):21. doi: 10.1007/s11926-018-0732-6. Review.

31.

Anti-HMGCR Myopathy.

Mohassel P, Mammen AL.

J Neuromuscul Dis. 2018;5(1):11-20. doi: 10.3233/JND-170282. Review.

32.

Mitochondrial DNA Deletions With Low-Level Heteroplasmy in Adult-Onset Myopathy.

Leung DG, Cohen JS, Michelle EH, Bai R, Mammen AL, Christopher-Stine L.

J Clin Neuromuscul Dis. 2018 Mar;19(3):117-123. doi: 10.1097/CND.0000000000000200.

33.

Anti-NT5C1A autoantibodies are associated with more severe disease in patients with juvenile myositis.

Yeker RM, Pinal-Fernandez I, Kishi T, Pak K, Targoff IN, Miller FW, Rider LG, Mammen AL; Childhood Myositis Heterogeneity Collaborative Study Group.

Ann Rheum Dis. 2018 May;77(5):714-719. doi: 10.1136/annrheumdis-2017-212436. Epub 2018 Jan 23.

34.

Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase autoantibody-positive necrotizing autoimmune myopathy with dermatomyositis-like eruption.

Parikh P, Tavee J, Soltanzadeh P, Mammen AL, McKeever P, Li Y.

Muscle Nerve. 2018 Jun;57(6):E135-E136. doi: 10.1002/mus.26072. Epub 2018 Feb 2. No abstract available.

35.

Statins: pros and cons.

Pinal-Fernandez I, Casal-Dominguez M, Mammen AL.

Med Clin (Barc). 2018 May 23;150(10):398-402. doi: 10.1016/j.medcli.2017.11.030. Epub 2017 Dec 29. Review. English, Spanish.

36.

224th ENMC International Workshop:: Clinico-sero-pathological classification of immune-mediated necrotizing myopathies Zandvoort, The Netherlands, 14-16 October 2016.

Allenbach Y, Mammen AL, Benveniste O, Stenzel W; Immune-Mediated Necrotizing Myopathies Working Group.

Neuromuscul Disord. 2018 Jan;28(1):87-99. doi: 10.1016/j.nmd.2017.09.016. Epub 2017 Oct 23. No abstract available.

PMID:
29221629
37.

Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis.

Johnson C, Rosen P, Lloyd T, Horton M, Christopher-Stine L, Oddis CV, Mammen AL, Danoff SK.

Respir Med. 2017 Sep;130:52-54. doi: 10.1016/j.rmed.2017.07.010. Epub 2017 Jul 17.

38.

High-dose cyclophosphamide without stem cell rescue in immune-mediated necrotizing myopathies.

Mecoli CA, Lahouti AH, Brodsky RA, Mammen AL, Christopher-Stine L.

Neurol Neuroimmunol Neuroinflamm. 2017 Jul 7;4(5):e381. doi: 10.1212/NXI.0000000000000381. eCollection 2017 Sep. Erratum in: Neurol Neuroimmunol Neuroinflamm. 2018 Jun 05;5(4):e473.

39.

Which nonautoimmune myopathies are most frequently misdiagnosed as myositis?

Mammen AL.

Curr Opin Rheumatol. 2017 Nov;29(6):618-622. doi: 10.1097/BOR.0000000000000441. Review.

40.

Association of Fibrosing Myopathy in Systemic Sclerosis and Higher Mortality.

Paik JJ, Wigley FM, Shah AA, Corse AM, Casciola-Rosen L, Hummers LK, Mammen AL.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1764-1770. doi: 10.1002/acr.23291.

41.

"Hiker's feet": a novel cutaneous finding in the inflammatory myopathies.

Cox JT, Gullotti DM, Mecoli CA, Lahouti AH, Albayda J, Paik J, Johnson C, Danoff SK, Mammen AL, Christopher-Stine L.

Clin Rheumatol. 2017 Jul;36(7):1683-1686. doi: 10.1007/s10067-017-3598-5. Epub 2017 Apr 7. Review.

42.

A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies.

Pinal-Fernandez I, Casal-Dominguez M, Huapaya JA, Albayda J, Paik JJ, Johnson C, Silhan L, Christopher-Stine L, Mammen AL, Danoff SK.

Rheumatology (Oxford). 2017 Jun 1;56(6):999-1007. doi: 10.1093/rheumatology/kex021.

43.

Calcium dysregulation, functional calpainopathy, and endoplasmic reticulum stress in sporadic inclusion body myositis.

Amici DR, Pinal-Fernandez I, Mázala DA, Lloyd TE, Corse AM, Christopher-Stine L, Mammen AL, Chin ER.

Acta Neuropathol Commun. 2017 Mar 22;5(1):24. doi: 10.1186/s40478-017-0427-7.

44.

Overlapping features of polymyositis and inclusion body myositis in HIV-infected patients.

Lloyd TE, Pinal-Fernandez I, Michelle EH, Christopher-Stine L, Pak K, Sacktor N, Mammen AL.

Neurology. 2017 Apr 11;88(15):1454-1460. doi: 10.1212/WNL.0000000000003821. Epub 2017 Mar 10.

45.

Association of Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase Autoantibodies With DRB1*07:01 and Severe Myositis in Juvenile Myositis Patients.

Kishi T, Rider LG, Pak K, Barillas-Arias L, Henrickson M, McCarthy PL, Shaham B, Weiss PF, Horkayne-Szakaly I, Targoff IN, Miller FW, Mammen AL; Childhood Myositis Heterogeneity Study Group.

Arthritis Care Res (Hoboken). 2017 Jul;69(7):1088-1094. doi: 10.1002/acr.23113.

46.

Sporadic inclusion body myositis - a myodegenerative disease or an inflammatory myopathy.

Weihl CC, Mammen AL.

Neuropathol Appl Neurobiol. 2017 Feb;43(1):82-91. doi: 10.1111/nan.12384. Review.

PMID:
28111778
47.

More severe disease and slower recovery in younger patients with anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase-associated autoimmune myopathy.

Tiniakou E, Pinal-Fernandez I, Lloyd TE, Albayda J, Paik J, Werner JL, Parks CA, Casciola-Rosen L, Christopher-Stine L, Mammen AL.

Rheumatology (Oxford). 2017 May 1;56(5):787-794. doi: 10.1093/rheumatology/kew470.

48.

Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.

Albayda J, Pinal-Fernandez I, Huang W, Parks C, Paik J, Casciola-Rosen L, Danoff SK, Johnson C, Christopher-Stine L, Mammen AL.

Arthritis Care Res (Hoboken). 2017 Nov;69(11):1771-1776. doi: 10.1002/acr.23188.

49.

Anti-3-hydroxy-3-methylglutaryl-coenzyme a reductase necrotizing myopathy masquerading as a muscular dystrophy in a child.

Mohassel P, Foley AR, Donkervoort S, Fequiere PR, Pak K, Bönnemann CG, Mammen AL.

Muscle Nerve. 2017 Dec;56(6):1177-1181. doi: 10.1002/mus.25567. Epub 2017 Apr 25.

PMID:
28066895
50.

Autoimmune Myopathies.

Mammen AL.

Continuum (Minneap Minn). 2016 Dec;22(6, Muscle and Neuromuscular Junction Disorders):1852-1870. Review.

Supplemental Content

Loading ...
Support Center